US-based medical device company Abbott has launched a next-generation delivery system for its Proclaim DRG neurostimulation system to optimise the implantation of electrodes.
The new delivery system supports patients with complex regional pain syndrome (CRPS) Type 1 and causalgia (CRPS Type 2) of the lower extremities.
The Proclaim DRG therapy targets the dorsal root ganglion (DRG), a cluster of nerve cells along the spine that controls pain signals from specific body areas.
It is the first and only DRG technology approved to treat CRPS of the lower limbs.
Abbott neuromodulation medical director Allen Burton said: “Research shows treating CRPS with targeted DRG neurostimulation results in significantly better outcomes in terms of pain relief and functional improvements than traditional spinal cord stimulation approaches.
“Abbott is continually working to improve DRG technology to better assist physicians in improving patient outcomes. The easier the procedure, the more patients will benefit from it, helping them to live more active, fuller lives with their chronic pain under control.”
The DRG neurostimulation system comprises an implantable pulse generator (IPG), which generates electrical stimulation and delivers the stimulation to the DRG.
Implanting a DRG lead involves accessing the epidural space with a needle and manoeuvring the lead toward the DRG under image guidance.
Once implanted, the system disrupts pain signals before they reach the spinal cord or brain.
The new delivery system for the Proclaim DRG system allows physicians to navigate and access the DRG’s precise anatomy when placing electrodes.
With enhanced durability and manoeuvrability, the next-generation delivery system aims to help physicians implant the DRG system more efficiently.
Spine and Nerve Centers of the Virginias’ president and CEO Timothy Deer said: “Because of the distinct position of the dorsal root ganglion near the spinal cord, it can be challenging to proficiently place leads there, which can limit the number of physicians who feel comfortable performing this procedure.
“The improved design of the new delivery system enhances manoeuvrability for physicians – potentially allowing more patients to experience the life-changing benefits of DRG stimulation.”
